220 related articles for article (PubMed ID: 23910709)
21. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy.
Chera BS; Rodriguez C; Morris CG; Louis D; Yeung D; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1173-80. PubMed ID: 19386423
[TBL] [Abstract][Full Text] [Related]
22. Intensity-modulated radiation therapy and volumetric-modulated arc therapy for adult craniospinal irradiation--a comparison with traditional techniques.
Studenski MT; Shen X; Yu Y; Xiao Y; Shi W; Biswas T; Werner-Wasik M; Harrison AS
Med Dosim; 2013; 38(1):48-54. PubMed ID: 22878118
[TBL] [Abstract][Full Text] [Related]
23. Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?
Aznar MC; Maraldo MV; Schut DA; Lundemann M; Brodin NP; Vogelius IR; Berthelsen AK; Specht L; Petersen PM
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):169-74. PubMed ID: 25754634
[TBL] [Abstract][Full Text] [Related]
24. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?
Girinsky T; Pichenot C; Beaudre A; Ghalibafian M; Lefkopoulos D
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):218-26. PubMed ID: 16169675
[TBL] [Abstract][Full Text] [Related]
25. Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks.
Murray L; Sethugavalar B; Robertshaw H; Bayman E; Thomas E; Gilson D; Prestwich RJ
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):401-10. PubMed ID: 25840609
[TBL] [Abstract][Full Text] [Related]
26. A decade of comparative dose planning studies for early-stage Hodgkin lymphoma: what can we learn?
Maraldo MV; Specht L
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1126-35. PubMed ID: 25539371
[TBL] [Abstract][Full Text] [Related]
27. The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma.
Maraldo MV; Jørgensen M; Brodin NP; Aznar MC; Vogelius IR; Petersen PM; Berthelsen AK; Christensen CB; Hjalgrim LL; Specht L
Pediatr Blood Cancer; 2014 Apr; 61(4):717-22. PubMed ID: 24660228
[TBL] [Abstract][Full Text] [Related]
28. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG).
Specht L; Yahalom J; Illidge T; Berthelsen AK; Constine LS; Eich HT; Girinsky T; Hoppe RT; Mauch P; Mikhaeel NG; Ng A;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):854-62. PubMed ID: 23790512
[TBL] [Abstract][Full Text] [Related]
29. Volumetric modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer.
Wolff D; Stieler F; Welzel G; Lorenz F; Abo-Madyan Y; Mai S; Herskind C; Polednik M; Steil V; Wenz F; Lohr F
Radiother Oncol; 2009 Nov; 93(2):226-33. PubMed ID: 19765846
[TBL] [Abstract][Full Text] [Related]
30. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk.
Koh ES; Tran TH; Heydarian M; Sachs RK; Tsang RW; Brenner DJ; Pintilie M; Xu T; Chung J; Paul N; Hodgson DC
Radiat Oncol; 2007 Mar; 2():13. PubMed ID: 17362522
[TBL] [Abstract][Full Text] [Related]
31. Interactive decision-support tool for risk-based radiation therapy plan comparison for Hodgkin lymphoma.
Brodin NP; Maraldo MV; Aznar MC; Vogelius IR; Petersen PM; Bentzen SM; Specht L
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):433-45. PubMed ID: 24321783
[TBL] [Abstract][Full Text] [Related]
32. Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin's lymphoma. Assessment of risk of toxicity and secondary cancer induction.
Scorsetti M; Cozzi L; Navarria P; Fogliata A; Rossi A; Franceschini D; De Rose F; Franzese C; Carlo-Stella C; Santoro A
Radiat Oncol; 2020 Jan; 15(1):12. PubMed ID: 31931861
[TBL] [Abstract][Full Text] [Related]
33. Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer.
Seco J; Gu G; Marcelos T; Kooy H; Willers H
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):188-94. PubMed ID: 23920395
[TBL] [Abstract][Full Text] [Related]
34. Proton therapy to the subdiaphragmatic region in the management of patients with Hodgkin lymphoma.
Sachsman S; Hoppe BS; Mendenhall NP; Holtzman A; Li Z; Slayton W; Joyce M; Sandler E; Flampouri S
Leuk Lymphoma; 2015 Jul; 56(7):2019-24. PubMed ID: 25315071
[TBL] [Abstract][Full Text] [Related]
35. Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.
Fox AM; Dosoretz AP; Mauch PM; Chen YH; Fisher DC; LaCasce AS; Freedman AS; Silver B; Ng AK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):277-83. PubMed ID: 22019238
[TBL] [Abstract][Full Text] [Related]
36. Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential.
Toltz A; Shin N; Mitrou E; Laude C; Freeman CR; Seuntjens J; Parker W; Roberge D
J Appl Clin Med Phys; 2015 Sep; 16(5):167–178. PubMed ID: 26699298
[TBL] [Abstract][Full Text] [Related]
37. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
[TBL] [Abstract][Full Text] [Related]
38. Comparison of passive-beam proton therapy, helical tomotherapy and 3D conformal radiation therapy in Hodgkin's lymphoma female patients receiving involved-field or involved site radiation therapy.
Horn S; Fournier-Bidoz N; Pernin V; Peurien D; Vaillant M; Dendale R; Fourquet A; Kirova YM
Cancer Radiother; 2016 Apr; 20(2):98-103. PubMed ID: 26992750
[TBL] [Abstract][Full Text] [Related]
39. 3-D reconstruction of anterior mantle-field techniques in Hodgkin's disease survivors: doses to cardiac structures.
Vordermark D; Seufert I; Schwab F; Kölbl O; Kung M; Angermann C; Flentje M
Radiat Oncol; 2006 Apr; 1():10. PubMed ID: 16722610
[TBL] [Abstract][Full Text] [Related]
40. Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy.
Loap P; Orlandi E; De Marzi L; Vitolo V; Barcellini A; Iannalfi A; Dendale R; Kirova Y; Mirandola A
Acta Oncol; 2022 Aug; 61(8):979-986. PubMed ID: 35668710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
